|Other Names||Cancer/testis antigen 2, CT2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 62, CT62, L antigen family member 1, LAGE-1, CTAG2, ESO2, LAGE1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13767c was selected from the Center region of CTAG2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Testis and very low level in placenta and in some uterus samples. Observed in 25-50% of tumor samples of melanomas, non-small-cell lung carcinomas, bladder, prostate and head and neck cancers|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes an autoimmunogenic tumor antigen thatbelongs to the ESO/LAGE family of cancer-testis antigens. Thisprotein is expressed in a wide array of cancers including melanoma,breast cancer, bladder cancer and prostate cancer. This protein isalso expressed in normal testis tissue. An alternative open readingframe product of this gene has been described in PMID 10399963.This alternate protein, termed CAMEL, is a tumor antigen that isrecognized by melanoma-specific cytotoxic T-lymphocytes. Alternatesplicing results in multiple transcript variants. [provided byRefSeq].
Wang, X.Y., et al. Oncol. Rep. 21(3):713-719(2009)Shao, Y., et al. J. Cancer Res. Clin. Oncol. 134(4):495-502(2008)Andrade, V.C., et al. Cancer Immun. 8, 2 (2008) :Kan, T., et al. Oncology 70(1):25-33(2006)Scanlan, M.J., et al. Immunol. Rev. 188, 22-32 (2002) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.